CoChat

Bupropion Efficacy for Smoking Cessation is Influenced by the DRD2 Taq1A Polymorphism: Analysis of Pooled Data from two Clinical Trials

Open access
David, Sean P., Strong, David R., Munafò, Marcus R., Brown, Richard A., Lloyd-Richardson, Elizabeth E., Wileyto, Paul E., Evins, Anne Eden, Shields, Peter G., Lerman, Caryn, Niaura, Raymond · 2007 · Nicotine & Tobacco Research
Cited by 80

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

We analyzed pooled data from two comparable randomized placebo-controlled clinical trials of bupropion pharmacotherapy for smoking cessation for which data on DRD2 Taq1A genotype were available. A total of 722 smokers across the two trials were randomized to 10 weeks of sustained-release bupropion hydrochloride or placebo. General estimating equation analysis demonstrated a significant gene x drug interaction (B = 0.87, SE = 0.34, p = .009). Smokers with the A2/A2 genotype using bupropion were more than three times as likely, relative to placebo, to be abstinent at end of treatment (35.2% vs. 15.1%; OR = 3.25, 95% CI 2.00-5.28) and at 6 months of follow-up (26.7% vs. 12.2%; OR = 2.81, 95% CI 1.66-4.77), which was attenuated by 12 months (16.3% vs. 10.7%; OR = 1.70, 95% CI 0.95-3.05). We found no significant benefit of bupropion relative to placebo on smoking cessation outcomes at any time point in participants with A1/A1 or A1/A2 genotypes. These data suggest that bupropion may be effective for smoking cessation only in a subgroup of smokers with the DRD2 Taq1 A2/A2 genotype.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/14622200701705027

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 80

Metadata

Authors
David, S. P., Strong, D. R., Munafò, M. R., Brown, R. A., Lloyd-Richardson, E. E., Wileyto, P. E., Evins, A. E., Shields, P. G., Lerman, C., & Niaura, R.
Venue
Nicotine & Tobacco Research
Published
2007-12
Volume
9
Issue
12
Pages
1251-1257
ISSN
  • 1462-2203 (ISSN-L)
  • 1469-994X
OpenAlex
W1994905981
Cited by
80
References
5
FWCI
5.54
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bupropion Efficacy for Smoking Cessation is Influenced by the DRD2 Taq1A Polymorphism: Analysis of Pooled Data from two Clinical Trials. https://app.cochat.ai/papers/10.1080/14622200701705027
The paper
David, S. P., Strong, D. R., Munafò, M. R., Brown, R. A., Lloyd-Richardson, E. E., Wileyto, P. E., Evins, A. E., Shields, P. G., Lerman, C., & Niaura, R. (2007). Bupropion Efficacy for Smoking Cessation is Influenced by the DRD2 Taq1A Polymorphism: Analysis of Pooled Data from two Clinical Trials. Nicotine & Tobacco Research. https://doi.org/10.1080/14622200701705027

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.